Earnings Summary

Elevance Health, Inc’s revenue jumped 5.36% since last year same period to $45145Mn in the Q3 2024. On a quarterly growth basis, Elevance Health, Inc has generated 3.43% jump in its revenue since last 3-months.

Elevance Health, Inc’s net profit fell -21.18% since last year same period to $1016Mn in the Q3 2024. On a quarterly growth basis, Elevance Health, Inc has generated -55.83% fall in its net profits since last 3-months.

Elevance Health, Inc’s net profit margin fell -25.19% since last year same period to 2.25% in the Q3 2024. On a quarterly growth basis, Elevance Health, Inc has generated -57.29% fall in its net profit margins since last 3-months.

Elevance Health, Inc’s price-to-earnings ratio after this Q3 2024 earnings stands at 14.66.

Elevance Health, Inc’s earning per share (EPS) estimates for the current quarter stand at 3.8 - a -60.66% fall from last quarter’s estimates.

Elevance Health, Inc’s earning per share (EPS) estimates for the current year stand at 3.8.

Elevance Health, Inc’s earning per share (EPS) fell -6.9% since last year same period to 8.37 in the Q3 2024. This indicates that the Elevance Health, Inc has generated -6.9% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Elevance Health, Inc’s return on assets (ROA) stands at 0.06.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Elevance Health, Inc’s return on equity (ROE) stands at 0.16.

Elevance Health, Inc declared 1.63 dividend per share during the earnings announcement for Q3 2024.